Northern Trust’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-18,200
Closed -$71.3K 4629
2023
Q3
$71.3K Buy
+18,200
New +$124K ﹤0.01% 4084
2023
Q2
Sell
-4,717
Closed -$17K 4615
2023
Q1
$17K Sell
4,717
-32
-0.7% -$494 ﹤0.01% 4474
2022
Q4
$153K Sell
4,749
-15
-0.3% -$594 ﹤0.01% 3966
2022
Q3
$199K Buy
4,764
+1,157
+32% +$52.9K ﹤0.01% 3878
2022
Q2
$152K Sell
3,607
-10,742
-75% -$498K ﹤0.01% 4021
2022
Q1
$973K Sell
14,349
-673
-4% -$56K ﹤0.01% 3428
2021
Q4
$1.82M Buy
15,022
+115
+0.8% +$19.4K ﹤0.01% 3261
2021
Q3
$2.1M Sell
14,907
-1,226
-8% -$243K ﹤0.01% 3264
2021
Q2
$4.43M Buy
16,133
+3,389
+27% +$855K ﹤0.01% 2910
2021
Q1
$2.73M Buy
12,744
+1,335
+12% +$369K ﹤0.01% 3085
2020
Q4
$2.76M Buy
11,409
+241
+2% +$29.8K ﹤0.01% 3020
2020
Q3
$1.18M Buy
11,168
+2,486
+29% +$226K ﹤0.01% 3318
2020
Q2
$851K Buy
8,682
+1,207
+16% +$106K ﹤0.01% 3407
2020
Q1
$561K Buy
7,475
+493
+7% +$46.9K ﹤0.01% 3419
2019
Q4
$567K Buy
6,982
+32
+0.5% +$3.58K ﹤0.01% 3529
2019
Q3
$847K Sell
6,950
-10
-0.1% -$1.38K ﹤0.01% 3435
2019
Q2
$1.25M Buy
6,960
+110
+2% +$17.8K ﹤0.01% 3287
2019
Q1
$1.1M Buy
6,850
+442
+7% +$87.5K ﹤0.01% 3330
2018
Q4
$1.67M Buy
6,408
+3,491
+120% +$703K ﹤0.01% 3148
2018
Q3
$711K Buy
2,917
+1,955
+203% +$512K ﹤0.01% 3558
2018
Q2
$227K Buy
+962
New +$280K ﹤0.01% 3817

Other funds holding EVLO

Northern Trust's EVLO Position: Q4 2023 in Review

Northern Trust sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q4 2023, closing a stake of 18,200 shares — an estimated $71.3K sold.

Northern Trust first reported a position in EVLO in Q2 2018 and held it in 21 quarters. The position peaked at $4.43M in Q2 2021. 2 funds tracked by Wall St. Rank hold EVLO as of Q4 2023.

  • Northern Trust reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Northern Trust sold 18,200 Evelo Biosciences, Inc. Common Stock shares in Q4 2023, an estimated $71.3K.
  • Northern Trust first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2018 and held it in 21 quarters.
  • Northern Trust's Evelo Biosciences, Inc. Common Stock position peaked at $4.43M in Q2 2021.
  • 2 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q4 2023.

Based on Northern Trust's 13F filing for Q4 2023, filed 13 Feb 2024.